(Total Views: 532)
Posted On: 05/07/2025 9:32:50 PM
Post# of 154726
OHM, thank you very much for sharing your analysis.
"There seems to be a couple of mistakes in that abstract." .
"The 30 month comparison is the closest long-term data we have to compare to our 4 year data. So that's .7% vs. 17.8%. In other words leronlimab is at least 25 times better very long term."
If you were going to edit the abstract to correct the errors, what would the changes be ?
"Leronlimab is at least 25 times better very long term" really caught my attention.This information is compelling and needs to shared widely.
Thank Ohm.
"There seems to be a couple of mistakes in that abstract." .
"The 30 month comparison is the closest long-term data we have to compare to our 4 year data. So that's .7% vs. 17.8%. In other words leronlimab is at least 25 times better very long term."
If you were going to edit the abstract to correct the errors, what would the changes be ?
"Leronlimab is at least 25 times better very long term" really caught my attention.This information is compelling and needs to shared widely.
Thank Ohm.
(9)
(0)
